A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Boon Cher Goh, M.D.
National University Hospital, Singapore
Principal Investigator - Charles Chuah, M.D.
Singapore General Hospital
Principal Investigator - George Wilding, M.D.
University of Wisconsin, Madison
Principal Investigator - Guillermo Garcia-Manero, MD
M.D. Anderson Cancer Center
Principal Investigator - Han Chong Toh, M.D.
National Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- National Cancer Center
Singapore, Singapore
- National University Hospital
Singapore, Singapore
- Singapore General Hospital
Singapore, Singapore
- Md Anderson Cancer Center
Houston, Texas, United States
- University of Wisconsin-Madison
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2007
- Primary completion
- 31 Mar 2012
- Completion
- 31 Mar 2012
- Last update posted
- 23 Apr 2012
- Registered enrollment
- 85
- Registry id
- NCT00741234
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.